Author(s): Akshay R. Yadav, Shrinivas K. Mohite

Email(s): akshayyadav24197@gmail.com

DOI: 10.5958/0975-4377.2020.00037.3   

Address: Akshay R. Yadav*, Shrinivas K. Mohite
Department of Pharmaceutical Chemistry, Rajarambapu College of Pharmacy, Kasegaon, Maharashtra, India-415404.
*Corresponding Author

Published In:   Volume - 12,      Issue - 3,     Year - 2020


ABSTRACT:
According to World Health Organization (WHO), Coronaviruses are a large family of viruses which can infect birds and mammals, including humans. At the end of 2019 in Wuhan, China, a novel coronavirus, known as 2019-nCoV, emerged. While COVID-19 and SARS-CoV belong to the same subgroup of beta corona virus, genome-level similarity is only 70 percent, and genetic differences from SARS-CoV have been identified in the novel group. Transfusion of convalescent blood products (CBP), especially convalescent plasma (CP), is useful if the latter induces neutralizing antibodies against emerging infectious agents. CBPs are extracted from a convalescent source by collecting whole blood or plasma apheresis. Passive immunization therapy was successfully implemented back to the 1890s to treat infectious diseases. An individual who is ill with infectious diseases and is recovering has blood drawn and screened for antibodies neutralizing specific microorganisms. After identifying those with high titers of neutralizing antibody, convalescent plasma containing such neutralizing antibodies can be administered to minimize symptoms and mortality in individuals with a specified clinical disease. Convalescent Plasma Transfusion (CPT) has been the subject of increasing attention, especially in the wake of large-scale epidemics.


Cite this article:
Akshay R. Yadav, Shrinivas K. Mohite. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Res. J. Pharma. Dosage Forms and Tech.2020; 12(3):227-230. doi: 10.5958/0975-4377.2020.00037.3


REFERENCES:
1. Gralinski L, Menachery V. Return of the Coronavirus: 2019- nCoV. Viruses. 2020; 12(2): 135.
2. Peiris, Lai S, Poon L. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003; 361(9366): 1319-1325.
3. Subissi L, Posthuma C, Collet A, Zevenhoven-Dobbe J, Gorbalenya A, Decroly E, Snijder E.J, Canard B, Imbert, I. One severe acute respiratory syndrome coronavirus proteincomplex integrates processive RNA polymerase and exonuclease activities. Proc. Natl. Acad. Sci. 2014; 111: E3900–E3909.
4. Armstrong J, Niemann H, Smeekens S, Rottier P, Warren G. Sequence and topology of a model intracellular membrane protein, E1 glycoprotein, from a coronavirus. Nat. 1984; 308(5961): 751– 752. 
5. Woo P, Huang Y, Lau S, Yuen K. Coronavirus genomics and bioinformatics analysis. Virus. 2010, 2: 1804-20.
6. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W. 2020. A Novel Coronavirus from Patients with Pneumonia in China. N Engl J Med. 2019; 382: 727-733.
7. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24: 44-46.
8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145: 599-609.
9. Fazekas G, Rosenwirth B, Dukor P, Gergely J, Rajnavolgyi E. IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol. 1994; 24: 3063-3067. 
10. Mostov K. Transepithelial transport of immunoglobulins. Annu Rev Immunol. 1994; 12: 63-84.
11. El-Ekiaby M, Sayed MA, Caron C, Burnouf S, El-Sharkawy N, Goubran H, Radosevich M, Goudemand J, Blum D, De Melo L, Soulié V, Adam J, Burnouf T. Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med. 2005; 20: 48-61.
12. Singh Y, Sawyer LS, Pinkoski LS, Dupuis KW, Hsu JC, Lin L, Corash L. Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfus. 2006; 46:1168-1177.
13. Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at-30°C. Vox Sangui. 2010; 98: 108-115.
14. Wong HK, Lee CK, Hung IF, Leung JN, Hong J, Yuen KY, Lin CK. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfus. 2010; 50: 1967-1971.
15. Dichtelmuller H, Rudnick D, Kloft M. Inactivation of Lipid Enveloped Viruses by Octanoic Acid Treatment of Immunoglobulin Solution. Biolog. 2002; 30: 135-142.
16. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sanguinis. 2010; 98:12-28.
17. Xu D, Zhang Z, Jin L, Chu F, Mao Y, Wang H, Liu M, Wang M, Zhang L, Gao GF, Wang FS. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. Eur J Clin Microbiol Infect Dis. 2005; 24: 165-171.
18. Liu W, Fontanet A, Zhang PH, Zhan L, Xin ZT, Baril L, Tang F, Lv H, Cao WC. Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome. J Infect Dis. 2006; 193: 792-795.
19. Yeh K, Chiueh T, Siu L. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005; 56: 919-922.
20. Choe PG, Perera R, Park WB, Song KH, Bang JH, Kim ES, Kim HB, Ko LWR, Park SW, Kim NJ, Lau EHY, Poon LLM, Peiris M, Oh MD. MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea. Emerg Infect Dis. 2015; 23: 1079-1084. 
21. Dean CL, Hooper JW, Dye JM. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States. Transfus. 2020; 12: 514-518.
22. Ko JH, Seok H, Cho SY, Ha YE, Baek JY, Kim SH, Kim YJ, Park JK, Chung CR, Kang ES, Cho D, Muller MA, Drosten C, Kang CI, Chung DR, Song JH, Peck KR. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018; 23: 617-622.
23. Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, Al-Dawood A, Al-Qahtani S, AlOmari A, Al-Hameed F, Hayden FG, Fowler R, Bouchama A, Shindo N, Al-Khairy K, Carson G, Taha Y, Sadat M, Alahmadi M. Feasibility of Using Convalescent Plasma Immunotherapy for MERSCoV Infection, Saudi Arabia. Emerg Infect Dis. 2016; 22: 1554-1561.
24. Hashem AM, Hassan AM, Tolah AM, et al. Amotosalen and ultraviolet A light efficiently inactivate MERS-coronavirus in human platelet concentrates. Transfus Med. 2019; 29: 434-441.
25.  Chun S, Chung CR, Ha YE, Han TH, Ki CS, Kang ES, Park JK, Peck KR, Cho D. Possible Transfusion-Related Acute Lung Injury Following Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome. Ann Lab Med. 2016; 36: 393-395.

Recomonded Articles:

Author(s): Hapse S.A., Bhagat B.V., Wagh V.S. , Kadaskar P.T.

DOI:         Access: Open Access Read More

Author(s): Chikoti Sneha Priya, M. Venkataswamy, Gandla Harshini, Pindrathi Pravalika, Sandhya Mandadi, Jahnavi Bandla

DOI: 10.5958/0975-4377.2019.00040.5         Access: Closed Access Read More

Author(s): Shivom, Shambaditya Goswami, Nikita Pal, Ravindra Pal Singh, Asheesh Singh, M V Kumudhavalli

DOI: 10.5958/0975-4377.2020.00038.5         Access: Closed Access Read More

Author(s): Akshay R. Yadav, Shrinivas K. Mohite

DOI: 10.5958/0975-4377.2020.00037.3         Access: Closed Access Read More

Research Journal of Pharmaceutical Dosage Forms and Technology (RJPDFT) is an international, peer-reviewed journal, devoted to pharmaceutical sciences. ...... Read more >>>

RNI: Not Available                     
DOI: 10.5958/0975-4377 


Recent Articles




Tags